# EDGAR Filing Document

**Accession Number:** 0001621672
**File Stem:** 0000000000-25-008301
**Filing Date:** 2025-8
**Character Count:** 9344
**Document Hash:** 3156a2967e7e822fcd406109b79a5954
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-008301.hdr.sgml**: 20260625

**ACCESSION NUMBER**: 0000000000-25-008301

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250807

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Super League Enterprise, Inc.
- **CENTRAL INDEX KEY:** 0001621672
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMPUTER INTEGRATED SYSTEMS DESIGN [7373]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 471990734
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-288730

**BUSINESS ADDRESS:**
- **STREET 1:** 2450 COLORADO AVE
- **STREET 2:** STE 100E
- **CITY:** SANTA MONICA
- **STATE:** CA
- **ZIP:** 90404
- **BUSINESS PHONE:** 213-421-1920

**MAIL ADDRESS:**
- **STREET 1:** 2450 COLORADO AVE
- **STREET 2:** STE 100E
- **CITY:** SANTA MONICA
- **STATE:** CA
- **ZIP:** 90404

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Super League Gaming, Inc.
- **DATE OF NAME CHANGE:** 20150924

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Nth Games, Inc.
- **DATE OF NAME CHANGE:** 20141007
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001437749-25-022943

## Text-Extract

```

                                                             August 7, 2025

Matthew Edelman
Chief Executive Officer
Super League Enterprise, Inc.
2450 Colorado Avenue, Suite 100E
Santa Monica, CA 90404

       Re: Super League Enterprise, Inc.
           Registration Statement on Form S-3
           Filed July 17, 2025
           File No. 333-288730
Dear Matthew Edelman:

       We have conducted a limited review of your registration statement and
have the
following comments.

        Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments.

Registration Statement on Form S-3
Prospectus Summary
The Offering, page 2

1.     Please disclose whether there is a floor price for the investor's
purchase price under
       the Equity Purchase Agreement. If not, expand your risk factor
disclosure to address
       the additional dilution that may occur with no floor price. In addition,
indicate that the
       investment amount paid by the investor under the Equity Purchase
Agreement for
       each put by the company is 92% of the lowest trading price for the three
consecutive
       trading days following the put date minus clearing costs equal to 6% of
the purchase
       price. Disclose the resulting total discount to the trading price the
investor will pay to
       the company for the shares.
 August 7, 2025
Page 2
2.     Disclose that you may not have access to the full $20 million amount
available under
       the Equity Purchase Agreement. To provide context, disclose the amount
of net
       proceeds you would receive under the Equity Purchase Agreement if you
issued to the
       investor all of the shares being registered based upon the most recent
trading price of
       your shares, taking into account the purchase price of 92% of the
trading price minus
       clearing costs equal to 6% of the purchase price. Also disclose the
total number of
       shares you would have to issue to obtain the $20 million maximum amount
under the
       Equity Purchase Agreement based upon your most recent share price,
purchase price
       and clearing costs.
3.     Please disclose the formula for adjusting the number of shares
underlying the pre-
       funded warrant and provide an example of how it will work. Also indicate
whether the
       investor may exercise the warrant and sell the shares prior to the final
determination
       of the number of shares underlying the warrant.
Risk Factors
Shares of our preferred stock have certain approval rights with respect to
issuances of
Common Stock..., page 9

4.     You indicate that, although you are required to receive consent from the
majority of
       holders of each series of Series AA Convertible Preferred Stock prior to
issuing the
       shares of common stock that are being offered and sold in the current
offering, you
       intend to receive ratification from the Series AA Convertible Preferred
after the
       consummation of the offering. Please explain why you are not seeking
such approval
       before the offering. Provide your analysis of how not obtaining the
required approval
       before the issuance of the shares will impact the valid issuance of the
shares being
       registered and your ability to receive an opinion of counsel that the
shares will, when
       sold, be legally issued, fully paid and non-assessable.
We received a notice from Nasdaq that our common stock may be delisted from
trading on
the Nasdaq Capital Market..., page 10

5.     Please update your disclosure regarding the status of your
non-compliance
       with Nasdaq Listing Rule 5550(b)(1), which requires the company to
maintain a
       minimum of $2,500,000 in stockholders    equity for continued listing on
The Nasdaq
       Capital Market. Disclose the date you submitted your plan of compliance
and whether
       you have received a response from Nasdaq.
The Equity Purchase Transaction, page 14

6.     Please revise to clarify why the warrant the company issued as a
commitment fee in
       connection with the Equity Purchase Agreement is considered a
"pre-funded" warrant.
       In this regard, it does not appear that the investor pre-paid any
consideration for the
       warrant. If you are using the term "pre-funded warrant" to indicate the
shares
       underlying the warrant are not intended to be included in the investor's
beneficial
       ownership, then please so indicate, and state that the investor did not
pre-pay any
       amount for the warrant. Finally, revise to clarify the approximate value
of the
       Commitment Fee as compared to the consideration paid.
 August 7, 2025
Page 3
7.     Please discuss the provision of the Equity Purchase Agreement that
limits the number
       of shares you may issue without seeking shareholder approval under
Nasdaq rules for
       the issuance of more than 176,177 shares under the Equity Line Agreement
and Pre-
       Funded Warrant. Disclose whether you intend to seek such shareholder
approval.
Plan of Distribution, page 15

8.     You indicate that the selling stockholder may engage in hedging
transactions and sell
       securities short. This appears inconsistent with Section 5.2 of the
Equity Purchase
       Agreement. Please advise or revise your disclosure.
General

9.     Please note that the resale of shares issuable under the Equity Purchase
Agreement
       must be registered on a form that the company is eligible to use for a
primary offering.
       For guidance, refer to Question 139.13 of the Securities Act Sections
Compliance and
       Disclosure Interpretations. It appears that the aggregate market value
of your common
       equity held by non- affiliates during the 60 days prior to July 17, 2025
did not exceed
       the $75 million threshold that General Instruction I.B.1 of Form S-3
specifies. If you
       are relying on General Instruction I.B.6 for Form S- 3 eligibility, tell
us how you have
       sufficient capacity to register the number of shares you are offering
for resale under
       the Equity Purchase Agreement, and include the information required
pursuant to
       Instruction 7 to General Instruction I.B.6. For guidance, refer to
Question 116.21 of
       the Securities Act Forms Compliance and Disclosure Interpretations.
Alternatively,
       please amend your registration statement on an appropriate form.
10.    Please disclose the number of shares being offered for resale under the
Equity
       Purchase Agreement on the prospectus cover page and throughout the
prospectus.
11.    Please disclose that the selling shareholder is an underwriter with
respect to the resale
       of the shares issuable under the Equity Purchase Agreement. For
guidance, refer
       to Question 139.13 of the Securities Act Sections Compliance and
Disclosure
       Interpretations.
 August 7, 2025
Page 4

        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Kathleen Krebs at 202-551-3350 or Matthew Derby at
202-551-3334
with any other questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Technology
cc:   Jack Kennedy, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._